Immuneering Statistics

Total Valuation

Immuneering has a market cap or net worth of $43.92 million. The enterprise value is -$37.28 million.

Market Cap	43.92M
Enterprise Value	-37.28M

Important Dates

The next estimated earnings date is Thursday, May 2, 2024, after market close.

Earnings Date	May 2, 2024
Ex-Dividend Date	n/a

Share Statistics

Immuneering has 29.28 million shares outstanding. The number of shares has increased by 7.69% in one year.

Shares Outstanding	29.28M
Shares Change (YoY)	+7.69%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	29.55%
Owned by Institutions (%)	38.54%
Float	16.85M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.48
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.36, with a Debt / Equity ratio of 0.05.

Current Ratio	11.36
Quick Ratio	n/a
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -52.50% and return on invested capital (ROIC) is -61.46%.

Return on Equity (ROE)	-52.50%
Return on Assets (ROA)	-47.60%
Return on Capital (ROIC)	-61.46%
Revenue Per Employee	n/a
Profits Per Employee	-$786,347
Employee Count	68
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -86.98% in the last 52 weeks. The beta is -0.89, so Immuneering's price volatility has been lower than the market average.

Beta (1Y)	-0.89
52-Week Price Change	-86.98%
50-Day Moving Average	3.96
200-Day Moving Average	6.64
Relative Strength Index (RSI)	23.76
Average Volume (30 Days)	701,551

Short Selling Information

The latest short interest is 2.88 million, so 9.82% of the outstanding shares have been sold short.

Short Interest	2.88M
Short Previous Month	2.61M
Short % of Shares Out	9.82%
Short % of Float	17.07%
Short Ratio (days to cover)	1.95

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-58.41M
Pretax Income	-53.47M
Net Income	-53.47M
EBITDA	-52.71M
EBIT	-53.47M
Earnings Per Share (EPS)	-$1.88

Full Income Statement

Balance Sheet

The company has $85.67 million in cash and $4.46 million in debt, giving a net cash position of $81.20 million or $2.77 per share.

Cash & Cash Equivalents	85.67M
Total Debt	4.46M
Net Cash	81.20M
Net Cash Per Share	$2.77
Equity / Book Value	90.58M
Book Value Per Share	3.09
Working Capital	81.24M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$48.97 million and capital expenditures -$342,746, giving a free cash flow of -$49.31 million.

Operating Cash Flow	-48.97M
Capital Expenditures	-342,746
Free Cash Flow	-49.31M
FCF Per Share	-$1.74

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immuneering does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.69%
Shareholder Yield	-7.69%
Earnings Yield	-121.73%
FCF Yield	-112.26%

Analyst Forecast

The average price target for Immuneering is $15.75, which is 950.00% higher than the current price. The consensus rating is "Buy".

Price Target	$15.75
Price Target Difference	950.00%
Analyst Consensus	Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-22.66%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2